TP53 and non-small cell lung carcinoma: Thus far, a Phase 1/2 trial has been conducted with survivin inhibitor YM155 in combination with carboplatin and paclitaxel for metastatic non-small cell lung cancer (NCT01100931), though patients were not restricted by TP53 status [178].